share_log

Avalo Therapeutics | 3: Initial statement of beneficial ownership of securities-Director Truex Samantha

SEC announcement ·  Apr 3 16:13
Summary by Moomoo AI
Samantha Truex, a director and 10% owner of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated March 28, 2024. The form, which was signed on April 3, 2024, by Donald R. Reynolds by power of attorney, indicates that no securities are beneficially owned. This filing is in accordance with Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 and is a standard requirement for directors and significant shareholders to report their ownership of a company's securities.
Samantha Truex, a director and 10% owner of Avalo Therapeutics, Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per a Form 3 submission dated March 28, 2024. The form, which was signed on April 3, 2024, by Donald R. Reynolds by power of attorney, indicates that no securities are beneficially owned. This filing is in accordance with Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 and is a standard requirement for directors and significant shareholders to report their ownership of a company's securities.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more